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INTRODUCTION
Recipients of solid organ transplants have an increased risk 
of developing certain types of malignancies as compared 
with that of the general population [1]. Liver transplantation 
has been increased over the last two decades in Korea, and 
its good outcome with long term survival has prompted an 
increase of post-transplant complications [2]. Among the 
neoplasms that can develop after liver transplantation, post 
transplant lymphoproliferative disorder (PTLD), lymphoma, 
malignant melanoma, cutaneous basal-cell and squamous 
cell carcinoma (SCC), and SCC in situ of the vulva have been 
reported [3]. 
Here we report on the first pediatric Korean case of widely 
spread-vulvar SCC in situ that developed 14 years after living- 
related donor liver transplantation. The present case is unique 
in that the vulvar SCC in situ was associated with infection by 
uncommon human papillomavirus (HPV) subtypes as well as 
high risk subtypes. 
CASE REPORT 
A 16-year-old girl presented with multiple verruocoid vulvar 
masses on both the labia majora and minora. The lesions were 
incidentally detected 16 months previously. She did not com-
plain of local symptoms. No gross abnormalities were found 
in the vagina. She denied any sexual intercourse history, but 
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Here we report the first Korean case of a girl who developed noninvasive squamous cell carcinoma of the vulva at the age 
of 16 years. She was taking tacrolimus, an immunosuppressive agent, after living- related liver transplantation. The vulvar 
masses were microscopically proved as vulvar intraepithelial neoplasm II and III, even squamous cell carcinoma in situ. Human 
papillomavirus subtypes (69 and 73) and human papillomavirus types (66, 70, 73, and 43) were detected in the vulvar mass 
and the cervicovaginal smear, respectively. The outcome of liver transplantation for children has been markedly improved 
during the last several decades. However, the present case highlights the need to perform periodic genital examinations for 
the adolescents after liver transplantation. In addition to the high risk and probable high subtypes, uncommonly found human 
papillomavirus subtypes were extracted from her vulvar cancer. The present case is the first to show the possible relationship 
between previously unknown and uncommon human papillomavirus subtypes and pediatric post-transplant vulvar squamous 
cell carcinoma. More attention should be paid to the vulvar and cervical surveillance of pediatric transplant recipients by both 
medical specialists and general physicians.
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her hymen was torn. At the age of 18 months, she underwent 
living-related donor liver transplantation from her mother due 
to neonatal hepatitis and subsequent cirrhosis. After that, she 
had been taking immunosuppressive agents, mainly tacroli-
mus (FK506, 2 mg daily). She experienced two bouts of acute 
cellular rejection in superimposed chronic advanced rejection. 
Steroid pulse therapy and an increased dosage of tacrolimus 
were administered each time. Two years earlier, a high fast-
ing glucose level (160 mg/dL) was noticed on the routine 
follow-up. Diabetes mellitus was diagnosed, and Novorapid 
(Aspart, Pen, 300 IU/3 mL per day) therapy was taken. She had 
been followed up every two months during the 14 years of 
the postoperative follow-up period. The laboratory findings, 
including the peripheral blood cell counts and except for the 
hyperglycemia, were within the normal levels. 
Wide excision of the bilateral labia majora and minora with 
skin grafts was done. The excised specimen showed that the 
largest cauliflower-shaped polypoid lesion measured 3.5x2.0x 
0.3 cm (Fig. 1). The vulvar lesions showed various degrees of 
vulvar intraepithelial neoplasm II and III. Some small uni  form 
basaloid cells showed hyperchromatic and coarse nu  clear 
chromatin, and the warty larger cells showed greater pleo-
morphism with koilocytotic changes near the surface (Fig. 2). 
Nonkeratinizing, basaloid type of SCC in situ was also found. A 
cervicovaginal smear showed multiple koilocytotic dys  plastic 
cells, and this was diagnosed as low grade squa  mous intraepi-
thelial lesion with HPV infection and mild dysplasia.
We also analyzed the HPV by a PCR-based DNA microar-
ray system provided by a HPV-DNA chip test (MyHPVChip; 
Biomedlab Co. Ltd., Seoul, Korea) and using paraffin blocks. 
The chip contains 32 type-specific probes that consist of 18 
high-risk HPV groups (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66, 68, 69, 70, 73) and 14 low-risk HPV groups (6, 11, 32, 
34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 62). HPV types 69 and 73 
and HPV types 66, 70, 73, and 43 were identified in the vulvar 
mass and the cervicovaginal smear, respectively. She had an 
uneventful postoperative recovery. There has been no recur-
rence during the 3 months of follow up and her blood glucose 
level is under control.
DISCUSSION
Liver transplantation is the standard of care for children with 
end-stage, irreversible liver disease. As with adults, the early 
major complications include rejection, opportunistic infection 
and PTLD, and especially in children [4]. Post-transplant dia-
betes mellitus, as shown in the present patient, is one of the 
frequent complications after liver transplantation, and it de-
velops in 10% to 30% of all these patients [3]. The mechanism 
of pediatric post-transplant diabetes is likely to be a result of 
both insulin deficiency and the insulin resistance of immuno-
suppressive agents, including steroids and tacrolimus [5]. After 
a long follow-up duration, there is an increased incidence of 
certain malignancies developing; the relative risk for malig-
nancies is two to three times higher than that in the general 
population [1,2]. The most common malignancies in pediatric 
transplant recipients are lymphomas and skin and lip carcino-
mas, whereas skin and lip carcinomas are the most common 
Fig. 1. Gross picture of the excised vulva masses shows multi  ple no­
dular lesions, making cauliflower­shaped lesions are conglomerated.
Fig. 2. Low power view shows a vulvar squamous intraepithelial 
lesion showing dysplasia with varying degrees, up to the upper 
surface (H&E, x100). Inset showing dyskeratotic cells and bizarre 
mitosis (H&E, x200).Pediatric vulvar cancer in a liver transplantation recipient
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in adults [6]. Vulvar SCC usually appears in postmenopausal 
women in the 7th and 8th decades of life. Despite the young 
age, the multicentric squamous intraepithelial lesion (vulva 
and uterine cervix) was detected as well as HPV-infection in 
the present case. Post-transplant recipients demonstrated a 
25- to 40-fold increased risk to develop vulvar carcinomas [7]. 
About 40% of vulvar SCCs are associated with HPV-infection. 
In one study, 100% of the vulvar lesions in post-transplant 
recipients were HPV-positive compared to 21-57% in immu-
nocompetent individuals [8]. Immunosuppression per se is 
a known risk factor for HPV oncogenic virus-disease, and im-
munosuppressive agents and HPV play synergistic roles in car-
cinogenesis [9]. HPV is widely accepted as a causative agent 
of anogenital cancer. To date, more than 118 HPV genotypes 
have been identified and sequenced, and about 40 can infect 
the genital tract and 12 are classified as oncogenes [10,11]. By 
their oncogenic potential, HPV types were classified as high 
risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), 
low risk (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108) and 
probable high risk (26, 53, and 66). HPV type 16 has previously 
shown to be the most common type in all countries including 
Korea [12]. However, HPV type 69, which is one of the sub-
types detected in our patient’s vulvar carcinoma, is previously 
unknown in genital SCC. A recent world-wide assessment of 
HPV genotypes has shown that the previously unknown HPV 
types, which were identified as type 26, 30, 61, 67, 69, 82, and 
91, comprise 1% of all the studied invasive cervical carcino-
mas [13]. The biological behaviors of the rare and uncommon 
HPV types have only been investigated in a few studies, and 
mostly included lesions that were cervical intraepithelial neo-
plasms and a few cases of invasive cervical cancer [9]. Little is 
known about the exact mechanism of HPV-associated vulvar 
carcinogenesis of these rare HPV types because of the insuf-
ficient epidemiological evidence. HPV vaccination is prophy-
lactic, and it is assumed that maximum effectiveness will be 
achieved by administration before exposure to HPV or viral 
reactivation because HPV vaccination may offer a boosting ef-
fect of previously acquired natural immunity [14]. Two recent 
vaccines, the recombinant quadrivalent HPV vaccine (Merck, 
Gardasil®) and the bivalent HPV recombinant vaccine (Galxo-
SmithKline, Cervarix®), can mainly prevent the HPV targeting 
types 16, 18, 6, 11, 31, and 9 for Gardasil and types 16, 18, 45, 
and 31 for Cervarix. However, these vaccines are not effective 
in protecting against other high-risk HPV types, including the 
above mentioned uncommon types, which were also found 
in the present case. 
In conclusion, the present case is the first reported Korean 
case of vulvar SCC that developed in an adolescent who was 
taking immunosuppressive drugs after liver transplantation. 
Specialized vaccination programs may be required in post-
transplant recipients because uncommonly found HPV sub-
types may be ascribed to the carcinogenesis of vulvar SCC, 
especially in immunocompromised patients. This case is the 
first to show that uncommon HPV subtypes are related to pe-
diatric post-transplant vulvar SCC. Albeit the incidence of pe-
diatric vulvar SCC is rare, physicians should carefully perform 
more regular periodic genital examinations in children and 
adolescent transplant recipients because of their long-term 
follow-up and improved survival. 
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